Intarcia Therapeutics, Inc. To Present At The 24th Annual JPMorgan Healthcare Conference
SAN FRANCISCO, Jan. 4 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held, biopharmaceutical company, today announced that it will present at the 24th Annual JPMorgan Healthcare Conference at 1:00 p.m. PST on Thursday, January 12, 2006, at the Westin St. Francis Hotel in San Francisco, California.
Alice Leung, President and Chief Executive Officer of Intarcia Therapeutics, will provide an update on the Company's clinical development program for the Atamestane combination therapy in hormone-dependent advanced breast cancer. Intarcia expects to announce results from its first phase 3 clinical trial of Atamestane in April 2006. The Company will also provide an update on its development program for Omega DUROS(R), a subcutaneous implant designed to deliver omega interferon for the treatment of hepatitis C.
Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, applies a targeted approach to the acquisition, development and commercialization of therapeutic products for use in treating patients with cancer and infectious diseases. Intarcia's lead programs include a combination therapy for the treatment of hormone-dependent breast cancer in postmenopausal women and an implant to deliver omega interferon for the treatment of hepatitis C.Photo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, email@example.comIntarcia Therapeutics, Inc.
CONTACT: James Ahlers, Chief Financial Officer of Intarcia Therapeutics,Inc., +1-510-652-2600, ext. 235
Web site: http://www.intarcia.com/